Fundraising Fox
Boston · Seed–Series A · 45 people tracked
Also known as Longwood · LONGWOOD MANAGEMENT LLC
Find your way into Longwood Fund
Sign up to see every warm intro you have to Longwood Fund
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Longwood Fund team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Longwood Fund focuses on creating and investing in novel healthcare and biotech companies that develop important treatments for patients. The firm acts as company co-founders and value-add investors, partnering with entrepreneurs, scientists, and academic innovators to turn groundbreaking discoveries into companies. It leverages its own company creation and operating experience to build businesses that both benefit patients and generate significant investor value. Its partners have founded over 20 biotech companies, which have launched roughly 25 drugs.
Source: firm website, verified Sep 29, 2026.
Team · 45 people
from the firm's website & curated & public directories
Founder mafia
The Longwood Fund mafia →7 people who came through Longwood Fund went on to found or lead other companies.
What they invest in
from 47 of 77 portfolio companiesBiotech ×39Healthtech ×26Medical Devices ×17AI & Machine Learning ×6Deep Tech ×5Digital Health ×5Consumer ×2Advanced Manufacturing ×1
HQs:United States×36Canada×1United Kingdom×1
Who they back
founder profiles across 18 portfolio companiesFounding team size:solo founder×82 founders×53 founders×14+ founders×4
Where their founders studiedfrom 19 founders with education data
KU Leuven ×3Imperial College London ×2UCL ×2Université Louis Pasteur (Strasbourg I) ×2
What their founders studiedfrom 20 founders with field-of-study data
Life Sciences ×12Medicine ×4Chemistry ×3Engineering ×2
Where their founders worked beforefrom 24 founders with career history
Galapagos ×9Aligos Therapeutics ×3Johnson & Johnson ×3Janssen Europe, Middle East & Africa (EMEA) ×2Maverick Therapeutics ×2MPM BioImpact ×2Potenza Therapeutics ×2Rigimmune ×2
14 founders hold a PhD · 1 hold an MBA (of 21 with degree data)
Investments · 77 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 32024 · 52023 · 22022 · 42021 · 62020 · 32019 · 32018 · 22017 · 12015 · 12014 · 133 dated
Camp4 Therapeutics develops antisense oligonucleotides targeting regulatory RNAs to increase gene expression and restore healthy protein levels for genetic diseases, with an initial focus on treating SYNGAP1-related developmental and epileptic encephalopathy.
BiotechCambridge, US
Richard Young(Director (Class II))Josh Mandel-Brehm(Chief Executive Officer and Director (Class III))in
BoardMICHAEL HIGGINS(Director)JORGE CONDE(Director)inAMIR NASHAT(Director)in
Board seatShaan C. Gandhi· per SEC Form D · filed Oct 2021
Co-investors5AM VenturesAndreessen HorowitzPolaris Partners
Pyxis Oncology develops antibody-drug conjugates and immunotherapies targeting difficult-to-treat cancers to improve patient outcomes.
BiotechDigital HealthHealthtechMedical DevicesBoston, US
Thomas Civik(Interim Chief Executive Officer, Director)
BoardGeeta Vemuri(Director)inJak Knowles(Director)John Flavin(Director)
Board seatDavid SteinbergChristoph Westphal· per SEC Form D
Co-investorsAgent CapitalLifeSci Venture PartnersPfizer Venture InvestmentsRA CapitalTrans-Pacific Technology FundRTW Investments L.P.
Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.
BiotechHealthtechCambridge, GB
Gregory Winter(Director)inNIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)MICHAEL SKYNNER(Executive Officer)in
Co-investorsAhren Innovation CapitalAstellas Venture Management LLCCambridge Innovation CapitalDementia Discovery FundRidgeback CapitalSR One Capital Management+4 more
GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesMenlo Park, US
Jeffrey T. Huber(Director)Joshua Ofman, MD, MSHS(Chief Executive Officer)inAaron Freidin(Executive Officer)inRobert Ragusa(Executive Officer, Director)Jennifer Cook(Executive Officer, Director)inRichard Klausner(Director)
Co-investorsAmino CapitalARCH Venture PartnersBezos ExpeditionsBluebird VenturesDecheng CapitalDentsu Ventures+13 more
-2.png)
PTC is a global pharmaceutical company focused on the discovery, development, and commercialization of medicines for patients with rare diseases who have few or no treatment options.
BiotechHealthtechSouth Plainfield, US
Stuart W. Peltz(Executive Officer, Director)Allan Jacobson(Director)inMark E. Boulding(Executive Officer)inChristine Utter(Executive Officer)inMarcio Souza(Executive Officer)inNeil Almstead(Executive Officer)in
Co-investorsBay City Capital
Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.
BiotechMedical DevicesNeedham, US
Robert WeinbergRICHARD ALDRICH(Director)AMY C. CAVERS(Executive Officer)inCATHY CAREW(Executive Officer)inJONATHAN PACHTER(Executive Officer)inROB GAGNON(Executive Officer)in
Co-investorsBessemer Venture PartnersCardinal PartnersForesite CapitalLightstone VenturesOberland CapitalViking Global+1 more
Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.
BiotechDigital HealthMedical DevicesSan Diego, US
Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)inVikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)
Co-investorsForesite CapitalNorwest Venture PartnersPivotal Life SciencesRiverVest Venture PartnersYsios Capitalabrdn plc+4 more
Newleos is a biopharmaceutical company developing therapies for neuropsychiatric and neurodevelopmental disorders.
Biotech
Federico Bolognani(Co-founder, Chief Medical Officer)Christoph Westphal(Co-founder, Director)
Photys Therapeutics develops bifunctional small-molecule medicines that use induced proximity to recruit kinases and drive targeted protein phosphorylation, aiming to modulate and repair disease-driving proteins.
BiotechHealthtechLongevityWaltham, US
Amit Choudhary(Scientific Founder)David Steinberg(Chairman & Founding CEO)inEdward Holson(Co-founder & CSO)inLizzie Ngo(Co-founder)inBrian Fenton(President & CEO)in
Co-investorsMPM BioImpact8VCMRL Ventures FundOno Venture Investment, Inc.
Sitryx is a biotechnology company, founded in 2018, developing therapeutics with a focus on immunometabolism.
BiotechDeep TechHealthtech
Co-investorsOxford Science EnterprisesSofinnova PartnersSV Health InvestorsDementia Discovery Fund
Anuncia Medical develops medical technology focused on cerebrospinal fluid (CSF) science and clinical strategy to advance hydrocephalus treatment.
BiotechHealthtechMedical DevicesScottsdale, US
Darryl Baker(Executive Officer)Elsa Abruzzo(Executive Officer, Director)in
BoardEdgar D Janotta(Director)Stanton Rowe(Director)Stephen Oesterle(Director)
Board seatDavid Donabedian· per SEC Form D · $16.4M raise · filed Nov 2025
Co-investorsArieal Southeast Angel PartnersXcellerant Ventures
HealthtechLexington, US
Barbara S. Fox(Executive Officer, Director)Eileen F. Bostwick(Executive Officer)David C. Dlesk(Executive Officer)David Poorvin(Executive Officer, Director)
BoardJonathan Fleming(Director)
Board seatDavid Donabedian· per SEC Form D · $5M raise · filed Jul 2015
Co-investorsBoston Harbor AngelsKeiretsu Forum
The page presents Pinco Casino, an online gambling platform offering slots, live casino, table games, and sports betting with a Turkish-language interface.
ConsumerGamingHealthtechBoston, US
Robert Kotin(Executive Officer, Director)Chen Schor(Director)Robert Hadfield(Executive Officer)John Lawrence(Executive Officer)
BoardGeeta Vemuri(Director)inDerek Yoon(Director)in
Board seatDavid Steinberg· per SEC Form D
Co-investorsAstellas Venture Management LLCDC Investment PartnersSolasta VenturesUTokyo Innovation Platform Co. Ltd.Agent Capital
Colorescience is a professional skincare brand that develops mineral-based sun protection (SPF), skincare, and color correction products, originally created for post-procedure skin and marketed for all ages and skin types.
ConsumerDirect to ConsumerHealthtechWellness & FitnessCarlsbad, US
Stephen Loomis(Executive Officer)Mary Fisher(Executive Officer, Director)inTheodore Ebel(Executive Officer)Josie Juncal-Schwarz(Executive Officer)
BoardM Bolyard(Director)Brian Dovey(Director)in
Board seatRichard Aldrich· per SEC Form D
Co-investors1315 CapitalAisling CapitalRevelation PartnersDomain AssociatesHealthCare Ventures, LLCMontreux Equity Partners+2 more
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.
BiotechDigital HealthMedical DevicesWaltham, US
Amanda Wagner(Executive Officer)Dan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)
BoardLaura Brass(Director)inKai Wucherpfennig(Director)
Board seatChristoph Westphal· per SEC Form D
Co-investorsAgent CapitalDC Investment PartnersLifelinkMedical Excellence CapitalNovartis Venture FundOno Venture Investment, Inc.+5 more
BiotechBoston, US
David Donabedian(Executive Officer, Director)inRobert Hadfield(Executive Officer)inJohn McCabe(Executive Officer)in
BoardMing Cheah(Director)inRaymond Camahort(Director)
Board seatChristoph Westphal· per SEC Form D
Co-investorsDCVC (Data Collective)DCVC BioArkin CapitalNovo Holdings
A company focused on developing clinical treatments aimed at improving patient outcomes.
BiotechHealthtechMedical DevicesBoston, US
David Southwell(Executive Officer, Director)inRobert Crane(Executive Officer)
BoardSteve Kraus(Director)inCampbell Murray(Director)inHannes Smarason(Director)in
Board seatChristoph WestphalChristoph WestphalLea Hachigian· per SEC Form D
Co-investorsAstellas Venture Management LLCBessemer Venture PartnersGV (Google Ventures)RA Capital6 Dimensions CapitalPitango
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)inMary Thistle(Director)Evan Thackaberry(Executive Officer)Suzanne Bruhn(Director)Gerhard Koenig(Director)
Board seatShaan C. Gandhi· per SEC Form D · $75M raise · filed Aug 2022
Co-investorsAtlas VentureLightstone VenturesPivotal Life SciencesVida VenturesHatteras Venture Partners
Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer.
BiotechHealthtechMedical DevicesWatertown, US
Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)Luke Evnin(Co-founder, Board member (Chairman))inDavid Cordo(Executive Officer)Alon Lazarus(Director)
BoardBriggs Morrison(Director)in
Board seatChristoph Westphal· per SEC Form D
Co-investorsDC Investment PartnersK2 HealthVenturesMPM BioImpactRA CapitalTaiho Ventures, LLC
Co-investorsNeva Sgr.Sofinnova PartnersXGEN VentureAtlas VentureForbion
Neomorph develops a molecular glue discovery platform to identify small-molecule medicines that degrade disease-causing proteins through targeted protein degradation.
AI & Machine LearningBiotechDeep TechSan Diego, US
Co-investorsDeerfield Management Company
HealthtechBoulder, US
Jason Myers(Executive Officer, Director)Christian LaPointe(Executive Officer)
BoardKyle Lefkoff(Director)inPaul Manning(Director)in
Co-investorsCrawley VenturesBoulder VenturesPBM CapitalREDMILESands Capital VenturesSoleus Capital
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.
BiotechSan Diego, US
Athena Countouriotis(Co-Founder, Chief Executive Officer)Mohammad Hirmand(Executive Officer)inPaolo Tombesi(Executive Officer)inScott Lipman(Executive Officer)inBrian Sun(Executive Officer)in
BoardCarl Gordon(Director)
Co-investorsDelos CapitalForesite CapitalINCE CapitalNew Enterprise Associates (NEA)OrbiMedQuan Capital+6 more
Restaurant tech company; $100M exit.
Co-investorsAnalog VenturesBranded Strategic HospitalityFour Acres CapitalGV (Google Ventures)Rally Ventures Management, LlcSupernode Ventures+2 more
BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support.
BiotechHealthtech
Neil Kumar(Founder)
Co-investorsAisling CapitalAmzak HealthEcoR1 CapitalFrazier Life SciencesHEALTHCARE ROYALTY PARTNERSSequoia Capital+2 more
Calithera Biosciences was a clinical-stage biopharmaceutical company developing small-molecule oncology drugs targeting tumor metabolism, including the glutaminase inhibitor telaglenastat.
BiotechSouth San Francisco, US
Susan M. Molineaux(Executive Officer, Director)inWilliam Waddill(Executive Officer)in
BoardJean M. George(Director)Deepa Pakianathan(Director)inRalph E. Christoffersen(Director)Jonathan Drachman(Director)
Co-investorsVenture Capital Investment ManagementThe Column Group
HealthtechEmeryville, US
Bill Malecki(Executive Officer)Daniel Burnett(Director)Ulric Cote(Executive Officer, Director)
BoardDr. Jason Hong(Director)Anthony Natale(Director)inCarter Mayer(Director)
Co-investorsAPERTURE Venture PartnersGreen Park & Golf VenturesScientific Health DevelopmentThird Point VenturesVHM
Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
AI & Machine LearningBiotech
Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)inMarie De Vulder(Chief Legal Officer Co-founder)inGuy Peeters(Chief Financial Officer Co-founder)inJohn-Paul Gallivan(Head of Development Co-founder)inFabrice Kolb(Head of Immunology Co-founder)inPieter Peeters(Operating & Technology Officer Co-founder)in
Co-investorsFinchley Healthcare VenturesLuma GroupSofinnova VenturesBAM ElevateForbionNovo Holdings+2 more
Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid.
BiotechHealthtechMedical DevicesSan Diego, US
James Mackay(President & Chief Executive Officer)inNihar Bhakta(Chief Medical Officer)inAshwin Ram(Chief Operating Officer)inDeAnne Reid(Chief Administrative Officer)in
Co-investorsCatalys PacificNovo HoldingsAN Venture PartnersFrazier Life SciencesLightstone Ventures
DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research.
BiotechHealthtechCambridge, US
Nenad Grmusa(Chief Executive Officer)inJohn McCabe(Chief Financial and Operating Officer)in
Co-investorsAlta PartnersAstellas Venture Management LLCDC Investment PartnersPfizer Venture InvestmentsUTokyo Innovation Platform Co. Ltd.Insight Partners+1 more
Evommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief.
BiotechHealthtechPalo Alto, US
Luis Pena(President & Chief Executive Officer)inJanice Drew(Executive Officer)David Cohen(Director)Gregory Moss(Executive Officer)Eugene Bauer(Executive Officer, Director)Francois Beaubien(Director)
Co-investorsAndera PartnersAvego BioScience CapitalB Capital GroupB4 CapitalBeiersdorf Innovation FundFemHealth Ventures+4 more
.jpeg){kind=logo}
Flex Pharma provides accessible generic vasodilator medications, including PDE5 inhibitors, to U.S. patients at lower costs than brand-name alternatives.
BiotechDigital HealthHealthtechMedical Devices
Dr. Rod MacKinnon(Founder)
Co-investorsBessemer Venture PartnersEcoR1 CapitalLightstone Ventures
Flexiv builds adaptive robots featuring force control, including the Rizon seven-axis robotic arm and Hesper robot controller.
Advanced ManufacturingAI & Machine LearningDeep TechEnergyHardwareRoboticsSilicon Valley, US
Shiquan Wang(Co-Founder and Chief Executive Officer)inXiyang Yeh(Co-Founder and Chief Technology Officer)in
Co-investorsZhenFundGaorong CapitalGaorong VenturesGSR VenturesInvusPlug and Play Ventures+1 more
IlluminOss Medical makes a light-curable, patient-conforming intramedullary implant for minimally invasive fracture repair.
Co-investorsExcel Venture ManagementPappas CapitalSlater Technology Fund
BiotechPhiladelphia, US
Philip R. Johnson, M.D.(Executive Officer, Director)inDora Mitchell(Executive Officer)Lori Forrest(Executive Officer)Leon Moulder, Jr.(Director)Benjamin Lund(Director)in
BoardTomas Kiselak(Director)
Co-investorsAgent CapitalDC Investment PartnersOUP (Osage University Partners)Pfizer Venture InvestmentsQuan CapitalBain Capital Life Sciences+3 more
KalVista Pharmaceuticals is a global biopharmaceutical company that develops oral therapies for rare diseases, starting with hereditary angioedema (HAE).
BiotechHealthtech
Co-investorsFrazier Life SciencesRA Capital
Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases.
BiotechMedical Devices
Co-investorsForesite CapitalNextech InvestAlexandriaLilly Asia Ventures
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
David King(Co-Founder & CSO)inMaria Fardis(CEO)inCadmus C. Rich(Chief Medical Officer)inElaine Stracker(General Counsel)in
Co-investorsAlta PartnersCatalio Capital Management, LPDC Investment PartnersFrazier Life SciencesLongitude CapitalBiotechnology Value Fund+2 more
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)inBrian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Co-investorsAgent CapitalGimvMission BiocapitalNovartis Venture FundOno Venture Investment, Inc.Pfizer Venture Investments+5 more
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.
BiotechDeep TechMedical DevicesWatertown, US
Dmitrij Hristodorov(Director)inChristopher Loose(Executive Officer, Director)Sanjay Magavi(Executive Officer)Marc-Olivier Turgeon(Director)in
BoardAleks Radovic-Moreno(Director)inDan Janney(Director)
Co-investorsAlta PartnersDolby Family VenturesMission BiocapitalService Provider CapitalForbion
Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.
BiotechHealthtech
Pete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDavid Mantusin
Co-investorsAdjuvant CapitalAsahi Kasei Corporate Venture CapitalDementia Discovery FundF-Prime CapitalJeito CapitalSR One Capital Management+4 more
Rectify Pharma is a biotechnology company developing therapies, with a pipeline that has included work in liver and metabolic disease areas.
BiotechDeep Tech
Rajesh Devraj(President and Chief Executive Officer)inRobert Hughes(Chief Scientific Officer)inPol Boudes(Chief Medical Officer)
Co-investorsAtlas VentureDC Investment PartnersForbion
Boston-based biotech developing drugs against the 'dark genome'/repeatome for autoimmune disease, cancer and neurodegeneration.
Benjamin Greenbaum(Founder)David Ting(Founder)Rosana Kapeller(Founder)
Co-investorsAndreessen HorowitzARCH Venture PartnersGV (Google Ventures)Luma GroupSanofi VenturesAbingworth+11 more
Sidewinder Therapeutics is a biotechnology company focused on oncology drug discovery and development, working on next-generation cancer treatments.
BiotechHealthtechMedical DevicesSan Diego, US
Eric Murphy(Chief Executive Officer, Co-Founder, & Director)in
Co-investorsAstellas Venture Management LLCDCVC (Data Collective)DCVC BioFrazier Life SciencesNovartis Venture FundOrbiMed+2 more
Solu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels.
BiotechHealthtech
Phil Vickers(CEO / Leadership)inMichael Boretti(Leadership)inBrandon Turunen(Leadership)inSergio Santillana(Leadership)Enda Moran(Leadership)inKelly Honohan(Leadership)in
Co-investorsAstellas Venture Management LLCPappas Capital
Xaira develops AI and machine learning tools for drug discovery and protein design, serving pharmaceutical and biotech companies.
AI & Machine LearningBiotechMedical DevicesSouth San Francisco, US
Hetu Kamisetty(Founder)Marc Tessier-Lavigne(Founder)inDr. Ci Chu(Chief Discovery Officer)Dr. Bo Wang(Chief AI Scientist)Dr. Ian McCaffery(SVP, Translational Science and Early Clinical Development)Bob Nelsen(Founder)
Co-investorsARCH Venture PartnersBreyer CapitalDeviation CapitalF-Prime CapitalForesite CapitalMenlo Ventures+5 more
XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage.
BiotechHealthtechMedical DevicesMalvern, US
Ronald Crystal(Founder and Advisor (Board Observer))Todd Rosengart(Founder; Board Observer)John Tucker(President and CEO)Albert Gianchetti(Executive Officer, Director)
BoardGlenn Batchelder(Director)inJames Cohen(Director)
Co-investorsLumira VenturesFountain Healthcare PartnersJeito CapitalSofinnova Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Alcyone TherapeuticsAxial BiotherapeuticsNeela TherapeuticsRecros MedicaRenoviaAavantgardeAavantgardebioAlnaraArcherBe BioBE BiopharmaBebiopharmaBicycle TherapeuticsCalitheraCarbonCrystalysCrystalys TherapeuticsDemDEM BioInteriusKalVista PharmaceuticalsMediarMillendoMillendo TherapeuticsMitobridgeRectifySidewinderSolu TherapeuticsWeaverWerewolf
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 10
6 IPOs · 4 acquisitions · showing 9Camp4 Therapeutics CorpNASDAQ: CAMPPyxis OncologyNASDAQ: PYXSBicycleNASDAQ: BCYCGrailNASDAQ: GRALPtcbioNASDAQ: PTCTVerastemNASDAQ: VSTMVigil Neuroscienceacq. by SanofiAlnaraacq. by Eli Lilly and CompanyMillendo Therapeuticsacq. by Tempest Therapeutics
Portfolio news
latest coverage across their companies
Coultreon · coultreon.com · Apr 28, 2026
Flexiv · finsmes.com · Mar 19, 2026
Solu · finsmes.com · Apr 9, 2025
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Bicycle | 3.9% | $14.00 | May 2019 | $9.8M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Longwood Fund made?
- Longwood Fund has 77 tracked investments, 10 of which have exited, including 5 dated in the last 24 months.
- What stage does Longwood Fund invest at?
- Longwood Fund invests at the Seed, Series A stages.
- What sectors does Longwood Fund focus on?
- Longwood Fund focuses on Biotech, Deep Tech, Healthtech, Medical Devices.
- Where is Longwood Fund located?
- Longwood Fund is headquartered in Boston, US.
- Does Longwood Fund lead rounds?
- Longwood Fund typically participates in rounds rather than leading them.
- Who does Longwood Fund co-invest with?
- Longwood Fund most often shares deals with DC Investment Partners, Frazier Life Sciences, Alta Partners, among 107 tracked co-investors.
- What size deals does Longwood Fund back?
- Across 8 deals with disclosed amounts, Longwood Fund has joined rounds of $22M – $125M (median $75.5M).
Images
Co-investors · 15
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
Alta Partners is a venture capital firm focused on the healthcare and life sciences sector, backing entrepreneurs building companies across biotechnology, therapeutics, and healthcare innovation.
Forbion is a global venture capital firm focused on advancing biotech innovations and other sustainable solutions aimed at improving human and planetary health.
Agent Capital is a healthcare venture capital firm that makes direct equity investments in novel, differentiated therapeutics and treatments addressing unmet patient needs, from preclinical through commercial stages.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
▶3 more co-investors
Longitude CapitalWestlake Village BioPartnersDe Novo Ventures
Firms observed investing alongside Longwood Fund, from public investor directories. Shared companies are the overlap with Longwood Fund's recorded portfolio.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Blackbird is a venture capital firm that backs founders from the earliest stages, with a focus on ambitious technology startups across Australia and New Zealand.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.